MARKET

RDHL

RDHL

Redhill Biopharm
NASDAQ
1.205
+0.015
+1.26%
After Hours: 1.219 +0.014 +1.18% 17:47 12/16 EST
OPEN
1.240
PREV CLOSE
1.190
HIGH
1.240
LOW
1.190
VOLUME
61.78K
TURNOVER
--
52 WEEK HIGH
7.43
52 WEEK LOW
1.010
MARKET CAP
4.01M
P/E (TTM)
-0.5262
1D
5D
1M
3M
1Y
5Y
1D
RedHill Biopharma’s Opaganib Shows Promise in Combating CLL Resistance
TipRanks · 1d ago
RedHill Biopharma Shared In Vivo Results, Indicating That Opaganib Combined With Venetoclax Reduces Chronic Lymphocytic Leukemia Cells By Half Compared To Controls
Benzinga · 1d ago
RedHill Biopharma announces in vivo results on opaganib, venetoclax
TipRanks · 1d ago
Weekly Report: what happened at RDHL last week (1208-1212)?
Weekly Report · 1d ago
Weekly Report: what happened at RDHL last week (1201-1205)?
Weekly Report · 12/08 10:10
RedHill Biopharma regains Nasdaq stockholders’ equity compliance
Seeking Alpha · 12/01 19:05
RedHill Biopharma Regains Nasdaq Compliance
TipRanks · 12/01 12:29
Weekly Report: what happened at RDHL last week (1124-1128)?
Weekly Report · 12/01 10:06
More
About RDHL
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

Webull offers RedHill Biopharma Ltd (ADR) stock information, including NASDAQ: RDHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDHL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RDHL stock methods without spending real money on the virtual paper trading platform.